Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544960 | 0.89 | MAPK14 (0.47) | ALDH1A1KDM4ESMN1; SMN2RAB9APOLB | |
| SCHEMBL5366062 | 0.74 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL2702362 | 0.74 | CNR2 (0.52) | ALDH1A1RAB9APOLBNPSR1CNR1 | |
| SCHEMBL2703860 | 0.74 | CNR2 (0.52) | ALDH1A1RAB9APOLBNPSR1CNR1 | |
| SCHEMBL2702366 | 0.74 | CNR2 (0.52) | ALDH1A1RAB9APOLBNPSR1CNR1 | |
| SCHEMBL5520536 | 0.72 | CNR1 (0.60) | ALDH1A1KDM4ESMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL5520596 | 0.72 | HRH3 (0.54) | CYP2D6 | |
| SCHEMBL4690341 | 0.72 | SIGMAR1 (0.47) | ALDH1A1KDM4ERAB9ACNR1CNR2 | |
| SCHEMBL4747833 | 0.72 | USP8 (0.57) | ALDH1A1KDM4ESMN1; SMN2RAB9ACNR1 | |
| SCHEMBL24379591 | 0.72 | NLRP3 (0.66) | ALDH1A1KDM4ESMN1; SMN2RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | ALDH1A1 1492/4885KDM4E 1408/4885SMN1; SMN2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.